drugset
drugset / Trial / NCT02283671

Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B

NCT02283671 ↗

Phase 1 Completed 20 enrolled Sara Varea
NaSingle-groupOpen-labelTreatment

Summary

First in human study to assess the tolerability and safety profile of treatment with dendritic cell in patients with multiple sclerosis or neuromyelitis optica.

Timeline

Start
2015-09
Primary completion
2019-07-10
Completion
2019-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolerogenic Dendritic cells loaded with myelin peptides Cell therapy — Intravenous

Indications

multiple sclerosis neuromyelitis optica